Trial reportLeukemia2014
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Abstract readClinical TrialLetter
In one paragraph
Trial report in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.The Lancet. Oncology · 2014Trial
- Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.Blood cancer journal · 2015Article
- Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo.British journal of clinical pharmacology · 2015Article
- Article
- Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Current hematologic malignancy reports · 2015Review
- Article
- Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Blood · 2014Review
- New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Review
- Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review.Therapeutic advances in hematology · 2014Review
- Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
D M Stephens1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
A S RuppertComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J A Jones1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J Woyach1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
K Maddocks1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
S M Jaglowski1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
L A Andritsos1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
J M Flynn1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
M R Grever1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
G LozanskiDivision of Hematopathology, Department of Pathology, The Ohio State University, Columbus, OH, USA.
A J Johnson1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
N Muthusamy1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
N A Heerema1] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Cytogenetics, Department of Pathology, The Ohio State University, Columbus, OH, USA.
J C Byrd1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WIERDA, WILLIAM GEORGE · 2000 to 2016
$59.5MTWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6MTranslational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MTargeted Therapy for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · PI ROGERS, KERRY ANNE, WOYACH, JENNIFER A. · 2013 to 2025
$5.3MNCI NIH HHS K12 CA133250NCI NIH HHS P01 CA081534NCI NIH HHS P01 CA095426NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA177292
Abstract
PubMed holds no abstract for this paper.
Indexed as
Chromosome DeletionMolecular Targeted TherapyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChromosomes, Human, Pair 17FemaleFollow-Up StudiesHumansIn Situ Hybridization, FluorescenceKaryotypingLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNeoplasm Recurrence, Local
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.